Literature DB >> 35353329

Does the ISCHEMIA Trial Apply to My Patients?

Vandan Upadhyaya1, Smitha Narayana Gowda2, Gustavo Porto3, Chirag P Bavishi4, Partha Sardar5, Riyaz Bashir6, Mustafa Emir Gokceer7, Saurav Chatterjee8.   

Abstract

PURPOSE OF REVIEW: The ISCHEMIA trial demonstrated no difference in myocardial infarction or death in patients with stable coronary disease and moderate or large ischemia territory treated either with invasive revascularization or optimal medical therapy. Whether the findings of the randomized control trial relates to real-world outcomes is uncertain. RECENT
FINDINGS: Contemporary guideline-directed medical therapy has had a significant impact on the prognosis of coronary artery disease. Various observational data appear to indicate limited generalizability of the ISCHEMIA trial in different populations. Further studies are warranted to evaluate the optimal modality of therapy in patients with stable coronary disease and moderate or severe ischemia. The applicability of ISCHEMIA and ISCHEMIA-CKD trials still requires further validation.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Antianginal; Chest pain; Coronary disease; Ischemic heart disease; Revascularization

Mesh:

Year:  2022        PMID: 35353329     DOI: 10.1007/s11886-022-01684-7

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   3.955


  14 in total

1.  Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study.

Authors:  Nico H J Pijls; William F Fearon; Pim A L Tonino; Uwe Siebert; Fumiaki Ikeno; Bernhard Bornschein; Marcel van't Veer; Volker Klauss; Ganesh Manoharan; Thomas Engstrøm; Keith G Oldroyd; Peter N Ver Lee; Philip A MacCarthy; Bernard De Bruyne
Journal:  J Am Coll Cardiol       Date:  2010-05-28       Impact factor: 24.094

2.  Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study.

Authors:  Nico H J Pijls; Pepijn van Schaardenburgh; Ganesh Manoharan; Eric Boersma; Jan-Willem Bech; Marcel van't Veer; Frits Bär; Jan Hoorntje; Jacques Koolen; William Wijns; Bernard de Bruyne
Journal:  J Am Coll Cardiol       Date:  2007-05-17       Impact factor: 24.094

3.  Early intravenous beta-blockers in patients with acute coronary syndrome--a meta-analysis of randomized trials.

Authors:  Saurav Chatterjee; Debanik Chaudhuri; Rajesh Vedanthan; Valentin Fuster; Borja Ibanez; Sripal Bangalore; Debabrata Mukherjee
Journal:  Int J Cardiol       Date:  2012-11-17       Impact factor: 4.164

4.  Development and validation of a short version of the Seattle angina questionnaire.

Authors:  Paul S Chan; Philip G Jones; Suzanne A Arnold; John A Spertus
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2014-09-02

5.  Predictors, Trends, and Outcomes (Among Older Patients ≥65 Years of Age) Associated With Beta-Blocker Use in Patients With Stable Angina Undergoing Elective Percutaneous Coronary Intervention: Insights From the NCDR Registry.

Authors:  Apurva A Motivala; Valay Parikh; Matthew Roe; David Dai; J Dawn Abbott; Abhiram Prasad; Debabrata Mukherjee
Journal:  JACC Cardiovasc Interv       Date:  2016-08-22       Impact factor: 11.195

6.  Angina 1 year after percutaneous coronary intervention: a report from the NHLBI Dynamic Registry.

Authors:  Richard Holubkov; Warren K Laskey; Amelia Haviland; James C Slater; Martial G Bourassa; Helen Aslanidou Vlachos; Howard A Cohen; David O Williams; Sheryl F Kelsey; Katherine M Detre
Journal:  Am Heart J       Date:  2002-11       Impact factor: 4.749

7.  Renin-angiotensin system blockade reduces cardiovascular events in nonheart failure, stable patients with prior coronary intervention.

Authors:  Young Choi; Sungmin Lim; Kwan Yong Lee; Ha-Wook Park; Jaeho Byeon; Byung-Hee Hwang; Jin Jin Kim; Yong-Seog Oh; Ho-Joong Youn; Wook Sung Jung; Ki-Bae Seung; Kiyuk Chang
Journal:  Coron Artery Dis       Date:  2018-09       Impact factor: 1.439

8.  Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists Collaboration.

Authors:  S Yusuf; D Zucker; P Peduzzi; L D Fisher; T Takaro; J W Kennedy; K Davis; T Killip; E Passamani; R Norris
Journal:  Lancet       Date:  1994-08-27       Impact factor: 79.321

9.  Initial Invasive or Conservative Strategy for Stable Coronary Disease.

Authors:  David J Maron; Judith S Hochman; Harmony R Reynolds; Sripal Bangalore; Sean M O'Brien; William E Boden; Bernard R Chaitman; Roxy Senior; Jose López-Sendón; Karen P Alexander; Renato D Lopes; Leslee J Shaw; Jeffrey S Berger; Jonathan D Newman; Mandeep S Sidhu; Shaun G Goodman; Witold Ruzyllo; Gilbert Gosselin; Aldo P Maggioni; Harvey D White; Balram Bhargava; James K Min; G B John Mancini; Daniel S Berman; Michael H Picard; Raymond Y Kwong; Ziad A Ali; Daniel B Mark; John A Spertus; Mangalath N Krishnan; Ahmed Elghamaz; Nagaraja Moorthy; Whady A Hueb; Marcin Demkow; Kreton Mavromatis; Olga Bockeria; Jesus Peteiro; Todd D Miller; Hanna Szwed; Rolf Doerr; Matyas Keltai; Joseph B Selvanayagam; P Gabriel Steg; Claes Held; Shun Kohsaka; Stavroula Mavromichalis; Ruth Kirby; Neal O Jeffries; Frank E Harrell; Frank W Rockhold; Samuel Broderick; T Bruce Ferguson; David O Williams; Robert A Harrington; Gregg W Stone; Yves Rosenberg
Journal:  N Engl J Med       Date:  2020-03-30       Impact factor: 91.245

Review 10.  Chronic Kidney Disease and Coronary Artery Disease: JACC State-of-the-Art Review.

Authors:  Mark J Sarnak; Kerstin Amann; Sripal Bangalore; João L Cavalcante; David M Charytan; Jonathan C Craig; John S Gill; Mark A Hlatky; Alan G Jardine; Ulf Landmesser; L Kristin Newby; Charles A Herzog; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Thomas H Marwick
Journal:  J Am Coll Cardiol       Date:  2019-10-08       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.